Substituted thienopyrroles as pad4 inhibitors

A compound of Formula (I):

• or a pharmaceutically acceptable salt thereof, wherein:
• Ring A is 4- to 15-membered heterocyclyl substituted with 1-4 R7;
• R1 is selected from CH3 and CD3;
• R2 is selected from H, C1-3 alkyl substituted with 0-5 Re, and —(CH2)r—C3-6 cycloalkyl with 0-5 Re;
• R3 is selected from F, Cl, Br, and —ORb;
• L is selected from —(CRdRd)0-3—, —NRa—, —S(O)p—, and —C(═O)—;
• R4 is selected from H, F, Cl, Br, —CN, —ORb, C1-6 alkyl substituted with 1-5 R5, aryl substituted with 1-5 R5, C3-12 cycloalkyl substituted with 1-5 R5, and heterocyclyl comprising carbon atoms and 1-3 heteroatoms selected from N, NR6, O, and S and substituted with 1-5 R5;
• R5, at each occurrence, is independently selected from H, F, Cl, Br, nitro, ═O, —C1-4alkyl substituted with 0-4 Re, C2-4alkenyl substituted with 0-4 Re, C2-4alkynyl substituted with 0-4 Re, —(CH2)rCN, —(CH2)rORb, (CH2)rS(O)pRc, —(CH2)rS(O)pNRaRa, —(CH2)rNRaS(O)pRc, —(CH2)rNRaRa, —(CH2)rNRaC(═O)Rb, —(CH2)rNRaC(═O)NRaRa, —(CH2)rC(═O)ORb, —(CH2)rC(═O)Rb, —(CH2)rOC(═O)Rb, —(CH2)rC(═O)NRaRa, —P(═O)(OC1-4alkyl)2, —P(═O)(C1-4alkyl)2, C3-6cycloalkyl substituted with 0-4 Re, aryl substituted with 0-4 Re, heterocyclyl substituted with 0-4 Re, and heteroaryl substituted with 0-4 Re;
• R6, at each occurrence, is independently selected from H, C1-3alkyl substituted with 0-5 Re, —C(═O)Rb, —C(═O)(CH2)NRaRa, —C(═O)(CH2)rNRaC(═O)Rb, —C(═O)ORb, —S(O)pRe, —S(O)pNRaRa, —(CH2)r—C3-6cycloalkyl substituted with 0-4 Re, —(CH2)r-aryl substituted with 0-4 Re, —(CH2)r-heterocyclyl substituted with 0-4 Re, and —(CH2)r-heteroaryl substituted with 0-4 Re;
• R7 is selected from H, F, Cl, CN, C1-3 alkyl, ═N—ORb, —(CH2)rORb, —(CH2)rNRaRa, —NRaC(═NH)C1-3alkyl, —NRaC(═O)ORb, carbocyclyl, and a heterocyclyl;
• alternatively, two R7 groups are taken together to form carbocyclyl or heterocyclyl;
• Ra, at each occurrence, is independently selected from H, C1-6 alkyl substituted with 0-5 Re, C2-6 alkenyl substituted with 0-5 Re, C2-6 alkynyl substituted with 0-5 Re, —(CH2)r—C3-10carbocyclyl substituted with 0-5 Re, and —(CH2)r-heterocyclyl substituted with 0-5 Re;
• or Ra and Ra together with the nitrogen atom to which they are both attached form a heterocyclic ring substituted with 0-5 Re;
• Rb, at each occurrence, is independently selected from H, C1-6 alkyl substituted with 0-5 Re, C2-6 alkenyl substituted with 0-5 Re, C2-6 alkynyl substituted with 0-5 Re, —(CH2)r—C3-10carbocyclyl substituted with 0-5 Re, and —(CH2)r-heterocyclyl substituted with 0-5 Re;
• Rc, at each occurrence, is independently selected from C1-6 alkyl substituted with 0-5 Re, C2-6alkenyl substituted with 0-5 Re, C2-6 alkynyl substituted with 0-5 Re, —(CH2)r—C3-6 carbocyclyl substituted with 0-5 Re, and —(CH2)r-heterocyclyl substituted with 0-5 Re;
• Rd, at each occurrence, is independently selected from H and C1-6 alkyl substituted with 0-5 Re;
• Re, at each occurrence, is independently selected from C1-6 alkyl substituted with 0-5 Rf, C2-6 alkenyl, C2-6 alkynyl, —(CH2)r—C3-6 cycloalkyl, —(CH2)r-aryl, F, Cl, Br, CN, NO2, ═O, —C(═O)OH, —C(═O)OC1-4alkyl, —(CH2)rOH, and —(CH2)rOC1-4alkyl;
• Rf, at each occurrence, is independently selected from H, F, Cl, Br, CN, OH, C1-5 alkyl optionally substituted with OH, C3-6 cycloalkyl, and phenyl;
• p, at each occurrence, is independently selected from zero, 1, and 2;
• r, at each occurrence, is independently selected from zero, 1, 2, 3, and 4;
• and
• provided when L is selected from —NRa—, —S(O)p—, and —C(═O)—, R4 is selected from aryl substituted with 1-5 R5, C3-12 cycloalkyl substituted with 1-5 R5, and heterocyclyl comprising carbon atoms and 1-3 heteroatoms selected from N, NR6, O, and S and substituted with 1-5 R5.